Objective To systematically review the proportions of infants with early exposure to antenatal
corticosteroids but born at term or late preterm, and short term and long term outcomes …

Lung surfactant is the first drug so far designed for the special needs of the newborn. In
1929, Von Neergard described lung hysteresis and proposed the role of surface forces. In …

Airway management is required during general anaesthesia and is essential for life-
threatening conditions such as cardiopulmonary resuscitation. Evidence from recent trials …

Objective To provide the best clinical practice guidance for surfactant use in preterm
neonates with respiratory distress syndrome (RDS). The RDS-Neonatal Expert Taskforce …

Lung ultrasound (LU) has emerged as the imaging technique of choice for the assessment
of neonates with respiratory distress syndrome (RDS) at the bedside. Scoring systems were …

The introduction of exogenous surfactant in the 1980s has resulted in an improved survival
of very preterm infants with respiratory distress syndrome. Randomized controlled trials …

Bronchopulmonary dysplasia (BPD) is one of the most devastating morbidities of preterm
infants. Antenatal factors like growth restriction and inflammation are risk factors for its …

Surfactant is a pivotal neonatal drug used both for respiratory distress syndrome due to
surfactant deficiency and for more complex surfactant dysfunctions (such as in case of …

Non-invasive modes of respiratory support have been shown to be the preferable way of
primary respiratory support of preterm infants with respiratory distress syndrome (RDS). The …

Drug delivery using a surfactant vehicle has the potential to prevent systemic side effects by
delivering therapeutic agents directly to the respiratory system. The inherent chemical …